Answers are grounded in this paper and cite their sources.
Retrospective intercomparison study evaluates radiotherapy toxicity and cancer risk in prostate cancer patients, indicating significant impacts.
This study aims to assess different advanced treatments modalities in terms of their toxicity NTCPs and the induced second primary cancers excess absolute risk (EARs) using in-house software "COUPOLE" in case of prostate cancer. A total of 72 patients (GI, GII, GIII, and GIV) were treated using: VMAT1, VMAT2, HT and 3D-CRT. The treatment was planned with 6 MV using VARIAN HDX 2100C, VERSA HD Linear Accelerator, TOMOTHERAPY and ELEKTA Synergy. The prescribed dose was 76 Gy/2 Gy/F for GI and GII and 71.3 Gy/2.3 Gy/F for GIII and GIV. The Normal Tissue Complication Probability NTCPs (%) results for rectum = 9.5, 7.1, 5.18, and 22.46 for GI, GII, GIII, and GIV. The NTCP (%) for bladder = 0.05 for GI; 0.041 for GII; 0.0 and 1.67 for GIII and GIV. The EAR (/10000PY) for rectum and bladder are: 0.07(GII), 1.71(GIII), 1.60(GIV), and 6.30(GI), 0.01 (GII), 0.46(GIII), and 0.46(GIV), respectively. Minor toxicity for OARs when using HT but the risk is significant for bladder for HT and VMAT.
No takes yet. Share an insight, caveat, or question.
Boughalia et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: